Skip to main content

Table 3 Highest grade completed

From: Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine

Variable

EUR group ( N=1217)

NE group ( N=800)

Total ( N=2017)

p-value

Highest Grade Completed, n (%)

    

Number of Patients

1213

799

2012

<.0001a

No Formal Education

3 (0.2)

0 (0.0)

3 (0.1)

 

Kindergarten

1 (0.1)

0 (0.0)

1 (0.0)

 

1st

5 (0.4)

0 (0.0)

5 (0.2)

 

2nd

26 (2.1)

1 (0.1)

27 (1.3)

 

3rd

5 (0.4)

0 (0.0)

5 (0.2)

 

4th

4 (0.3)

0 (0.0)

4 (0.2)

 

5th

2 (0.2)

0 (0.0)

2 (0.1)

 

6th

4 (0.3)

0 (0.0)

4 (0.2)

 

7th

6 (0.5)

0 (0.0)

6 (0.3)

 

8th

12 (1.0)

0 (0.0)

12 (0.6)

 

9th

31 (2.5)

4 (0.5)

35 (1.7)

 

10th

16 (1.3)

10 (1.3)

26 (1.3)

 

11th

10 (0.8)

24 (3.0)

34 (1.7)

 

12th

49 (4.0)

12 (1.5)

61 (3.0)

 

High School

171 (14.1)

130 (16.3)

301 (14.9)

 

Primary Education

77 (6.3)

2 (0.3)

79 (3.9)

 

Secondary Education

302 (24.8)

22 (2.8)

324 (16.1)

 

Vocational Training

121 (9.9)

32 (4.0)

153 (7.6)

 

Some College

53 (4.4)

251 (31.4)

304 (15.1)

 

College

80 (6.6)

148 (18.5)

228 (11.3)

 

University Education

159 (13.1)

87 (10.9)

246 (12.2)

 

Some Graduate School

62 (5.1)

21 (2.6)

83 (4.1)

 

Post-Graduate

14 (1.2)

55 (6.9)

69 (3.4)

 
  1. Abbreviations: EUR = European; N = total number of patients; NE = non-European.
  2. ap-values are from chi-square test.